ALEXANDER LAZAR to Antibodies, Monoclonal, Humanized
This is a "connection" page, showing publications ALEXANDER LAZAR has written about Antibodies, Monoclonal, Humanized.
Connection Strength
0.319
-
Correlative Analyses of the SARC028 Trial Reveal an Association Between Sarcoma-Associated Immune Infiltrate and Response to Pembrolizumab. Clin Cancer Res. 2020 03 15; 26(6):1258-1266.
Score: 0.075
-
Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial. Lancet Oncol. 2017 11; 18(11):1493-1501.
Score: 0.064
-
Escalation to weekly dosing recaptures response in adalimumab-treated patients with moderately to severely active ulcerative colitis. Aliment Pharmacol Ther. 2014 Sep; 40(5):486-97.
Score: 0.051
-
Activity of temozolomide and bevacizumab in the treatment of locally advanced, recurrent, and metastatic hemangiopericytoma and malignant solitary fibrous tumor. Cancer. 2011 Nov 01; 117(21):4939-47.
Score: 0.041
-
Metastatic hidradenocarcinoma with demonstration of Her-2/neu gene amplification by fluorescence in situ hybridization: potential treatment implications. J Cutan Pathol. 2007 Jan; 34(1):49-54.
Score: 0.031
-
Durvalumab plus tremelimumab in advanced or metastatic soft tissue and bone sarcomas: a single-centre phase 2 trial. Lancet Oncol. 2022 09; 23(9):1156-1166.
Score: 0.022
-
B cells are associated with survival and immunotherapy response in sarcoma. Nature. 2020 01; 577(7791):556-560.
Score: 0.019
-
IGF-1R and mTOR Blockade: Novel Resistance Mechanisms and Synergistic Drug Combinations for Ewing Sarcoma. J Natl Cancer Inst. 2016 12; 108(12).
Score: 0.015